Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1980 Dec;66(6):1383–1390. doi: 10.1172/JCI109991

Immunoreactive β-Endorphin and Adrenocorticotropin in Human Cerebrospinal Fluid

Kazuwa Nakao 1,2,3, Shogo Oki 1,2,3, Issey Tanaka 1,2,3, Kazuko Horii 1,2,3, Yoshikatsu Nakai 1,2,3, Tomoo Furui 1,2,3, Masanori Fukushima 1,2,3, Akio Kuwayama 1,2,3, Naoki Kageyama 1,2,3, Hiroo Imura 1,2,3
PMCID: PMC371624  PMID: 6255011

Abstract

To elucidate the significance of β-endorphin in human cerebrospinal fluid (CSF), CSF levels of β-endorphin-like immunoreactivity (β-EP-LI) in various diseases were determined by a specific radioimmunoassay and compared with simultaneously determined ACTH-like immunoreactivity (ACTH-LI) levels in CSF. CSF β-EP-LI and ACTH-LI in the control group, consisting of 5 normal subjects and 19 patients with nonendocrine diseases, were 22.2±1.3 and 14.6±0.4 fmol/ml, respectively. CSF levels of these peptides in patients with schizophrenia (n = 19) and acromegaly (n = 10) were not significantly different from those in the control group. Patients with Cushing's disease (n = 7) had significantly lower CSF β-EP-LI and ACTH-LI levels than those in the control group. Four of them showed a parallel increase in CSF β-EP-LI and CSF ACTH-LI levels after the complete removal of pituitary microadenomas (P < 0.05).

Gel chromatography of CSF β-EP-LI from a normal volunteer, a control patient, and one patient each with catatonia, Nelson's syndrome, Cushing's syndrome (adrenal adenoma), and acromegaly gave similar patterns consisting of three peaks with the elution positions comparable to those of authentic β-endorphin, β-lipotropin, and possibly their precursor molecule.

Gel chromatographic patterns of CSF β-EP-LI and ACTH-LI were compared in a normal volunteer. The first peaks of β-EP-LI and ACTH-LI eluted at the same position and the second peak of ACTH-LI coincided with the elution position of authentic ACTH.

CSF β-EP-LI and ACTH-LI levels determined every 5 min over a period of 80 min in three normal volunteers did not show moment-to-moment variability.

A significant correlation (r = 0.75, P < 0.001) was seen between CSF β-EP-LI and ACTH-LI levels in normal subjects and patients studied (n = 73). This suggests that β-endorphin and ACTH in human CSF share the common regulatory mechanism in normal and pathologic conditions.

Full text

PDF
1383

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berson S. A., Yalow R. S. Radioimmunoassay of ACTH in plasma. J Clin Invest. 1968 Dec;47(12):2725–2751. doi: 10.1172/JCI105955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bloom F., Battenberg E., Rossier J., Ling N., Guillemin R. Neurons containing beta-endorphin in rat brain exist separately from those containing enkephalin: immunocytochemical studies. Proc Natl Acad Sci U S A. 1978 Mar;75(3):1591–1595. doi: 10.1073/pnas.75.3.1591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bloom F., Segal D., Ling N., Guillemin R. Endorphins: profound behavioral effects in rats suggest new etiological factors in mental illness. Science. 1976 Nov 5;194(4265):630–632. doi: 10.1126/science.185694. [DOI] [PubMed] [Google Scholar]
  4. Davis G. C., Bunney W. E., Jr, DeFraites E. G., Kleinman J. E., van Kammen D. P., Post R. M., Wyatt R. J. Intravenous naloxone administration in schizophrenia and affective illness. Science. 1977 Jul 1;197(4298):74–77. doi: 10.1126/science.325650. [DOI] [PubMed] [Google Scholar]
  5. Domschke W., Dickschas A., Mitznegg P. C.S.F. beta-endorphin in schizophrenia. Lancet. 1979 May 12;1(8124):1024–1024. doi: 10.1016/s0140-6736(79)92769-7. [DOI] [PubMed] [Google Scholar]
  6. Foley K. M., Kourides I. A., Inturrisi C. E., Kaiko R. F., Zaroulis C. G., Posner J. B., Houde R. W., Li C. H. beta-Endorphin: analgesic and hormonal effects in humans. Proc Natl Acad Sci U S A. 1979 Oct;76(10):5377–5381. doi: 10.1073/pnas.76.10.5377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gramsch C., Höllt V., Mehraein P., Pasi A., Herz A. Regional distribution of methionine-enkephalin- and beta-endorphin-like immunoreactivity in human brain and pituitary. Brain Res. 1979 Aug 3;171(2):261–270. doi: 10.1016/0006-8993(79)90332-9. [DOI] [PubMed] [Google Scholar]
  8. Gunne L. M., Lindström L., Terenius L. Naloxone-induced reversal of schizophrenic hallucinations. J Neural Transm. 1977;40(1):13–19. doi: 10.1007/BF01250276. [DOI] [PubMed] [Google Scholar]
  9. Hosobuchi Y., Rossier J., Bloom F. E., Guillemin R. Stimulation of human periaqueductal gray for pain relief increases immunoreactive beta-endorphin in ventricular fluid. Science. 1979 Jan 19;203(4377):279–281. doi: 10.1126/science.83674. [DOI] [PubMed] [Google Scholar]
  10. Höllt V., Müller O. A., Fahlbusch R. beta-Endorphin in human plasma: basal and pathologically elevated levels. Life Sci. 1979 Jul 2;25(1):37–44. doi: 10.1016/0024-3205(79)90487-9. [DOI] [PubMed] [Google Scholar]
  11. Janowsky D. S., Segal D. S., Bloom F., Abrams A., Guillemin R. Lack of effect on naloxone on schizophrenic symptoms. Am J Psychiatry. 1977 Aug;134(8):926–927. doi: 10.1176/ajp.134.8.926. [DOI] [PubMed] [Google Scholar]
  12. Jeffcoate W. J., Rees L. H., McLoughlin L., Ratter S. J., Hope J., Lowry P. J., Besser G. M. beta-Endorphin in human cerebrospinal fluid. Lancet. 1978 Jul 15;2(8081):119–121. doi: 10.1016/s0140-6736(78)91506-4. [DOI] [PubMed] [Google Scholar]
  13. Kato Y., Iwasaki Y., Abe H., Ohgo S., Imura H. Effects of endorphins on prolactin and growth hormone secretion in rats. Proc Soc Exp Biol Med. 1978 Jul;158(3):431–436. doi: 10.3181/00379727-158-40219. [DOI] [PubMed] [Google Scholar]
  14. Kleerekoper M., Donald R. A., Posen S. Corticotrophin in cerebrospinal fluid of patients with Nelson's syndrome. Lancet. 1972 Jan 8;1(7741):74–76. doi: 10.1016/s0140-6736(72)90068-2. [DOI] [PubMed] [Google Scholar]
  15. Kurland A. A., McCabe O. L., Hanlon T. E., Sullivan D. The treatment of perceptual disturbances in schizophrenia with naloxone hydrochloride. Am J Psychiatry. 1977 Dec;134(12):1408–1410. doi: 10.1176/ajp.134.12.1408. [DOI] [PubMed] [Google Scholar]
  16. Loh H. H., Tseng L. F., Wei E., Li C. H. beta-endorphin is a potent analgesic agent. Proc Natl Acad Sci U S A. 1976 Aug;73(8):2895–2898. doi: 10.1073/pnas.73.8.2895. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Mains R. E., Eipper B. A., Ling N. Common precursor to corticotropins and endorphins. Proc Natl Acad Sci U S A. 1977 Jul;74(7):3014–3018. doi: 10.1073/pnas.74.7.3014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Matsukura S., Yoshimi H., Sueoka S., Kataoka K., Ono T., Ohgushi N. The regional distribution of immunoreactive beta-endorphin in the monkey brain. Brain Res. 1978 Dec 22;159(1):228–233. doi: 10.1016/0006-8993(78)90125-7. [DOI] [PubMed] [Google Scholar]
  19. Meglio M., Hosobuchi Y., Loh H. H., Adams J. E., Li C. H. beta-Endorphin: behavioral and analgesic activity in cats. Proc Natl Acad Sci U S A. 1977 Feb;74(2):774–776. doi: 10.1073/pnas.74.2.774. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Nakai Y., Nakao K., Oki S., Imura H., Li C. H. Presence of immunoreactive beta-endorphin in plasma of patients with Nelson's syndrome and Addison's disease. Life Sci. 1978 Dec 4;23(23):2293–2298. doi: 10.1016/0024-3205(78)90194-7. [DOI] [PubMed] [Google Scholar]
  21. Nakai Y., Nakao K., Oli S., Imura H. Presence of immunoreactive beta-lipotropin and beta-endorphin in human placenta. Life Sci. 1978 Nov 13;23(20):2013–2018. doi: 10.1016/0024-3205(78)90233-3. [DOI] [PubMed] [Google Scholar]
  22. Nakanishi S., Inoue A., Taii S., Numa S. Cell-free translation product containing corticotropin and beta-endorphin encoded by messenger RNA from anterior lobe and intermediate lobe of bovine pituitary. FEBS Lett. 1977 Dec 1;84(1):105–109. doi: 10.1016/0014-5793(77)81067-3. [DOI] [PubMed] [Google Scholar]
  23. Nakao K., Nakai Y., Jingami H., Oki S., Fukata J., Imura H. Substantial rise of plasma beta-endorphin levels after insulin-induced hypoglycemia in human subjects. J Clin Endocrinol Metab. 1979 Dec;49(6):838–841. doi: 10.1210/jcem-49-6-838. [DOI] [PubMed] [Google Scholar]
  24. Nakao K., Nakai Y., Oki S., Horii K., Imura H. Presence of immunoreactive beta-endorphin in normal human plasma: a concomitant release of beta-endorphin with adrenocorticotropin after metyrapone administration. J Clin Invest. 1978 Dec;62(6):1395–1398. doi: 10.1172/JCI109261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Nakao K., Nakai Y., Oki S., Matsubara S., Konishi T., Nishitani H., Imura H. Immunoreactive beta-endorphin in human cerebrospinal fluid. J Clin Endocrinol Metab. 1980 Feb;50(2):230–233. doi: 10.1210/jcem-50-2-230. [DOI] [PubMed] [Google Scholar]
  26. Ross M., Berger P. A., Goldstein A. Plasma beta-endorphin immunoreactivity in schizophrenia. Science. 1979 Sep 14;205(4411):1163–1164. doi: 10.1126/science.472735. [DOI] [PubMed] [Google Scholar]
  27. Smyth D. G., Massey D. E., Zakarian S., Finnie M. D. Endorphins are stored in biologically active and inactive forms: isolation of alpha-N-acetyl peptides. Nature. 1979 May 17;279(5710):252–254. doi: 10.1038/279252a0. [DOI] [PubMed] [Google Scholar]
  28. Suda T., Liotta A. S., Krieger D. T. beta-Endorphin is not detectable in plasma from normal human subjects. Science. 1978 Oct 13;202(4364):221–223. doi: 10.1126/science.211585. [DOI] [PubMed] [Google Scholar]
  29. Volavka J., Mallya A., Baig S., Perez-Cruet J. Naloxone in chronic schizophrenia. Science. 1977 Jun 10;196(4295):1227–1228. doi: 10.1126/science.860138. [DOI] [PubMed] [Google Scholar]
  30. Watson S. J., Akil H., Berger P. A., Barchas J. D. Some observations on the opiate peptides and schizophrenia. Arch Gen Psychiatry. 1979 Jan;36(1):35–41. doi: 10.1001/archpsyc.1979.01780010041004. [DOI] [PubMed] [Google Scholar]
  31. Watson S. J., Akil H., Richard C. W., 3rd, Barchas J. D. Evidence for two separate opiate peptide neuronal systems. Nature. 1978 Sep 21;275(5677):226–228. doi: 10.1038/275226a0. [DOI] [PubMed] [Google Scholar]
  32. Watson S. J., Berger P. A., Akil H., Mills M. J., Barchas J. D. Effects of naloxone on schizophrenia: reduction in hallucinations in a subpopulation of subjects. Science. 1978 Jul 7;201(4350):73–76. doi: 10.1126/science.351804. [DOI] [PubMed] [Google Scholar]
  33. Wiedemann E., Saito T., Linfoot J. A., Li C. H. Specific radioimmunoassay of human beta-endorphin in unextracted plasma. J Clin Endocrinol Metab. 1979 Sep;49(3):478–480. doi: 10.1210/jcem-49-3-478. [DOI] [PubMed] [Google Scholar]
  34. Yoshimi H., Matsukura S., Sueoka S., Fukase M., Yokota M., Hirata Y., Imura H. Radioimmunoassay for beta-endorphin: presence of immunoreactive "big-big" beta-endorphin ("big" beta-lipotropin) in human and rat pituitaries. Life Sci. 1978 Jun 26;22(24):2189–2195. doi: 10.1016/0024-3205(78)90570-2. [DOI] [PubMed] [Google Scholar]
  35. Zakarian S., Smyth D. Distribution of active and inactive forms of endorphins in rat pituitary and brain. Proc Natl Acad Sci U S A. 1979 Nov;76(11):5972–5976. doi: 10.1073/pnas.76.11.5972. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES